← Human Trials & Peer-Reviewed Studies
Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial.
Plain-language guide to PMID 35294969 (2022): double-blind randomized controlled trial of Copper (Supplement) in 21,442 adults.
Key Facts
- PMID
- 35294969
- Journal
- The American journal of clinical nutrition
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Sesso HD et al. (16 authors)
- DOI
- 10.1093/ajcn/nqac056
- Registered trial
- NCT02422745
What This Study Did, in Plain Language
What Was Tested
Researchers studied Copper (Supplement) in this randomized controlled trial publication.
Who Took Part
The study group was 21,442 adults.
The age groups tagged for this paper are older adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the adults and researchers unaware of who received Copper (Supplement).
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
The intervention phase was from June 2015 through December 2020.
This article reports on the MVM intervention.
The primary outcome was total invasive cancer, excluding nonmelanoma skin cancer.
Secondary outcomes included major site-specific cancers, total CVD, all-cause mortality, and total cancer risk among those with a baseline history of cancer.
What Was Measured
The subject headings attached to it are Breast Neoplasms, Cacao, Cardiovascular Diseases, Dietary Supplements, Health Promotion and Vitamins.
The authors tagged it with the keywords cancer, cocoa extract, flavanols, multivitamin and randomized clinical trial.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 21,442 adults.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (The American journal of clinical nutrition), a journal based in United States.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.